DUBLIN – Ablynx NV joined the great European biopharma migration to Nasdaq, grossing just over $200 million in an upsized IPO of 11.43 million shares, which it priced at $17.50 per American Depository Share (ADS). The offering brings its total number of shares outstanding to over 72.8 million and implies a market cap just shy of $1.3 billion.

DUBLIN – Shares in DBV Technologies Inc. plunged on news that its Viaskin peanut allergy therapy failed to reach statistical significance in a pivotal phase III trial in children. The most immediate beneficiary was Aimmune Therapeutics Inc., of Brisbane, Calif., whose stock rose by more than one-third Monday, with investor attention switching to its AR-101 oral desensitization therapy, which is currently undergoing a phase III trial in children and adults.

DUBLIN – ADC Therapeutics SA (ADCT) closed $200 million in a private financing round, the fourth largest on record for a European biopharmaceutical firm.

DUBLIN – The EMA aims, as best it can, to maintain a business-as-usual stance in the run-up to Brexit and the agency's associated departure from London. But its "Brexit Preparedness Business Continuity Plan," which it published late on Monday, sets out in stark terms the extent to which it may be forced to depart from that agenda given the massive disruption to its day-to-day operations brought on by the U.K.'s decision to exit the European Union.

DUBLIN – The fundraising momentum the European biopharmaceutical sector developed in the final week of September continued into the early weeks of the fourth quarter, with substantial levels of private and public investment activity in evidence across multiple geographies and markets.

DUBLIN – Virionhealth Ltd., a newly funded U.K. startup, raised up to £13 million (US$17 million) in series A funding to take forward a novel approach for preventing and treating respiratory viral infections, which relies on a long-recognized quirk of viral replication that has long been overlooked by the biotechnology industry.

DUBLIN – Turnstone Biologics Inc. entered a research, option and license agreement with Abbvie Inc., which it claims is the biggest such deal on record in the rapidly emerging area of oncolytic viruses.

DUBLIN – Immatics AG raised $58 million in a series E round that brought in Amgen Inc. as a new investor. The financing, among the top three private equity rounds closed this year by a European biotech, is confirmation that the Tuebingen, Germany-based company remains at the front rank of Europe’s immuno-oncology firms.

DUBLIN – A flurry of deals in late September added a burst of energy to what was otherwise a pretty sleepy third quarter for European biotech firms engaged in drug development. The last week of the month – and of the quarter – was a particularly busy one. European firms raised $472 million during that time, more than half of the total third-quarter raise, which came to $837 million.

DUBLIN – Three firms made a late addition to the harvest this year. Deciphera Pharmaceuticals Inc, Nightstar Therapeutics plc and Nucana plc priced IPOs late Thursday, raising $302.5 million in aggregate and taking the total raised from IPOs in the third quarter to $965 million.